vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $12.5M, roughly 1.5× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -90.7%, a 92.0% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -0.7%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
NAMS vs SLSN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $12.5M |
| Net Profit | $-17.4M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -186.1% | 1.5% |
| Net Margin | -90.7% | 1.3% |
| Revenue YoY | 740.1% | -0.7% |
| Net Profit YoY | 55.5% | 129.2% |
| EPS (diluted) | $-0.15 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | $19.1M | $20.4M | ||
| Q1 25 | — | $14.6M | ||
| Q4 24 | $12.8M | $12.6M | ||
| Q3 24 | $29.1M | $16.9M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-17.4M | $2.7M | ||
| Q1 25 | — | $80.0K | ||
| Q4 24 | $-92.2M | $-559.0K | ||
| Q3 24 | $-16.6M | $3.0M | ||
| Q2 24 | — | $856.0K | ||
| Q1 24 | — | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | -186.1% | 9.4% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | -338.5% | -1.8% | ||
| Q3 24 | -85.9% | 19.0% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | -90.7% | 13.1% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | -721.7% | -4.4% | ||
| Q3 24 | -57.2% | 18.1% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | $-0.15 | $0.04 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | $-0.91 | $0.00 | ||
| Q3 24 | $-0.18 | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $17.6M |
| Total Assets | $815.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $429.0K | ||
| Q2 25 | $739.2M | $4.1M | ||
| Q1 25 | — | $1.8M | ||
| Q4 24 | $834.2M | $1.4M | ||
| Q3 24 | $422.7M | $2.9M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.2M | ||
| Q2 25 | $778.5M | $18.2M | ||
| Q1 25 | — | $15.2M | ||
| Q4 24 | $757.5M | $14.9M | ||
| Q3 24 | $378.9M | $15.2M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | — | $54.0M | ||
| Q2 25 | $815.1M | $60.0M | ||
| Q1 25 | — | $57.0M | ||
| Q4 24 | $864.6M | $50.0M | ||
| Q3 24 | $439.2M | $48.0M | ||
| Q2 24 | — | $40.8M | ||
| Q1 24 | — | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $1.8M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | $-37.7M | $-654.0K | ||
| Q1 25 | — | $-7.2M | ||
| Q4 24 | $-37.5M | $2.2M | ||
| Q3 24 | $-12.5M | $4.2M | ||
| Q2 24 | — | $-565.0K | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | $-404.0K | ||
| Q3 24 | $-12.6M | $2.8M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | -3.2% | ||
| Q3 24 | -43.2% | 16.6% | ||
| Q2 24 | — | -8.0% | ||
| Q1 24 | — | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | 20.6% | ||
| Q3 24 | 0.3% | 8.3% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
